July 27, 2016 7:07 PM ET

Pharmaceuticals

Company Overview of Anchen Pharmaceuticals, Inc.

Company Overview

Anchen Pharmaceuticals, Inc. engages in the development, manufacture, marketing, distribution, and sale of specialty pharmaceutical products to patients primarily in the United States. It focuses on the development and commercialization of generic products and new drug products that fulfill unmet medical needs. The company also provides tretinoin capsules for the treatment of acute promyelocytic leukemia. The company was founded in 2004 and is headquartered in Irvine, California. Anchen Pharmaceuticals, Inc. operates as a subsidiary of Anchen Incorporated.

9601 Jeronimo Road

Irvine, CA 92618-2025

United States

Founded in 2004

Phone:

949-837-6178

Fax:

949-837-6120

Key Executives for Anchen Pharmaceuticals, Inc.

Senior Vice President of Regulatory Affairs
Compensation as of Fiscal Year 2016.

Anchen Pharmaceuticals, Inc. Key Developments

Sucampo Pharmaceuticals, Inc., Sucampo AG, R-Tech Ueno, Ltd. and Takeda Pharmaceutical Company Limited Enters into Settlement and License Agreement with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc

Sucampo Pharmaceuticals, Inc. announced that it, its affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Limited and certain affiliates of Takeda have entered into a settlement and license agreement with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. that resolves patent litigation in the United States (U.S.) related to Sucampo's AMITIZA(R) (lubiprostone) 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule. Under the terms of the settlement, Sucampo and RTU will grant Par a non-exclusive license to market Par's generic version of lubiprostone 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule (licensed products) in the U.S. for the indications approved for AMITIZA(R) beginning January 1, 2021, or earlier under certain circumstances. Beginning on January 1, 2021, Par will split with Sucampo the gross profits of the licensed products sold during the term of the agreement, which continues until each of the Sucampo patents has expired. In the event Par elects to launch an authorized generic, Sucampo will supply Par under the terms of a manufacturing and supply agreement at a negotiated price. Additional details of the agreement remain confidential. Additionally, Sucampo, RTU, Takeda, and Par have agreed to dismiss with prejudice the patent litigation filed in the United States District Court for the District of Delaware.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Anchen Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.